KRAS mutation has been suggested as an important predicator to resistance of antiepidermal growth factor and can be a prognostic factor of treatment outcomes in CRC patients with oligometastatic disease.26,30 In our study, histological and molecular mutation for every treated site was not confirmed and thus KRAS mutation for every treated site is unknown and cannot be included in the analysis. Here, KRAS is linked to colorectal carcinoma.